4D Molecular Therapeutics FDMT Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's additional paid-in capital?
- 4D Molecular Therapeutics (FDMT) reported additional paid-in capital of $1.24B in Q1 2026.
- How has 4D Molecular Therapeutics's additional paid-in capital changed year-over-year?
- 4D Molecular Therapeutics's additional paid-in capital increased by 13.1% year-over-year, from $1.09B to $1.24B.
- What is the long-term trend for 4D Molecular Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's additional paid-in capital has grown at a 25.5% compound annual growth rate (CAGR), from $392.06M to $1.22B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.